• PTC Therapeutics Chief Technical Ops Officer Neil Gregory Almstead exercised options for 23,749 shares at USD 25.69 on June 22, 2026.
• He sold 23,749 shares the same day at weighted average prices of USD 80.61 and USD 81.21.
• Directly held common stock fell to 60,137 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001578850-26-000014), on June 24, 2026, and is solely responsible for the information contained therein.